{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:20:47Z","timestamp":1791580847235,"version":"4.3.4"},"reference-count":11,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2016,12,3]]},"abstract":"<jats:p>The Food and Drug Administration (FDA) had approved fingolimod usage for multiple sclerosis in 2010. Melanoma after the usage of fingolimod immunomodulation was reported rarely in clinical trials, and only two case reports exist in the published literature, both occurring in Europe. Most of the incidences reported in clinical trials were in-situ, whereas both case reports were of malignant melanoma. Fingolimod has been found to inhibit metastatic melanoma growth in a mouse model that depends on vascular endothelial growth factor (VEGF)-induced angiogenesis for metastasis. However, there are numerous pathways of angiogenesis and tumour growth found in vivo by which melanoma can expand that do not mandate VEGF. We report a case of superficial spreading malignant melanoma occurring after fingolimod therapy in the USA.<\/jats:p>","DOI":"10.1136\/bcr-2016-217885","type":"journal-article","created":{"date-parts":[[2016,12,21]],"date-time":"2016-12-21T16:21:08Z","timestamp":1482337268000},"page":"bcr2016217885","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Fingolimod (Gilenya) and melanoma"],"prefix":"10.1136","volume":"2016","author":[{"given":"Christopher Lee","family":"Robinson","sequence":"first","affiliation":[{"name":"Department of Dermatology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St. Louis University, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,12,21]]},"reference":[{"key":"2025082703403802000_2016.dec21_1.bcr2016217885.1","unstructured":"FDA approves first oral drug to reduce MS relapses [Internet]. Fda.gov. 2016 (cited 23 June 2016). http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm226755.htm"},{"key":"2025082703403802000_2016.dec21_1.bcr2016217885.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907839"},{"key":"2025082703403802000_2016.dec21_1.bcr2016217885.3","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2001"},{"key":"2025082703403802000_2016.dec21_1.bcr2016217885.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052643"},{"key":"2025082703403802000_2016.dec21_1.bcr2016217885.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909494"},{"key":"2025082703403802000_2016.dec21_1.bcr2016217885.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01314-8"},{"key":"2025082703403802000_2016.dec21_1.bcr2016217885.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70049-3"},{"key":"2025082703403802000_2016.dec21_1.bcr2016217885.8","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.212"},{"key":"2025082703403802000_2016.dec21_1.bcr2016217885.9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/ced.12770","article-title":"Superficial spreading malignant melanoma in a patient on fingolimod therapy for multiple sclerosis","volume":"41","author":"Haebich","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"2025082703403802000_2016.dec21_1.bcr2016217885.10","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514564489"},{"key":"2025082703403802000_2016.dec21_1.bcr2016217885.11","doi-asserted-by":"crossref","unstructured":"Timmons JJ , Cohessy S , Wong ET . Injection of syngeneic murine melanoma cells to determine their metastatic potential in the lungs. J Vis Exp 2016; doi:10.3791\/54039 doi:10.3791\/54039","DOI":"10.3791\/54039"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2016-217885","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:40:41Z","timestamp":1756291241000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2016-217885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,21]]},"references-count":11,"alternative-id":["10.1136\/bcr-2016-217885"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2016-217885","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,21]]}}}